How did patients respond to
treatment with XPOVIO® (selinexor)?
In the clinical trial, 134 adults with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) were treated with XPOVIO 60 mg on Days 1 and 3 of every week. The FDA approval was based upon the results of this trial, and additional trials may be needed.
Response to XPOVIO was evaluated in patients regardless of status (n=39):
- Their age
- The number of treatments they had taken before
- The type of diffuse large B-cell lymphoma (DLBCL) they have
- If their DLBCL had stopped responding to other treatments
- If they had previously had a stem cell transplant
Patients who responded did not need to take XPOVIO with another anti‑cancer medicine.
How long did responses to XPOVIO last?
Patients who responded to XPOVIO had a rapid and meaningful response.
*The median duration of response (DOR) was a prespecified secondary outcome, determined by a particular statistical analysis. Limitations to this analysis for the data from this study include a small number of patients and the effect of data from patients with prolonged remission durations. Approximately half of the responders in this analysis had a DOR lasting less than 3 months.
The analysis of DOR is presented alongside an analysis demonstrating the number of patients responding at certain timepoints (3, 6, 12 months).
The median number is the middle point of a set of numbers, in which half the numbers are above the median and half are below.